Parkinson's disease (PD) is one of the common neurodegenerative disorders. Recently, the cross-talk of gut-brain has become a spotlight as a potential underlying approach for the development of PD treatment. Committed to the development of NGPs for years, Creative Biolabs has extensive experience in this field. Our excellent scientists will provide global researchers with high-quality NGPs development services.
Parkinson's disease (PD) stands in second place after Alzheimer's disease among common neurodegenerative disorders. The onset of PD is usually at 65 years and older age, and it appears slightly more frequently in men than in women. The aging of society around the globe is predicted to increase the population affected by PD and result in challenges for the provision of medical and socio-economic care. PD typically is known to be associated with the progressive loss of dopaminergic neurons in substantia nigra pars compacta. Motor impairment, characterized by resting tremor, muscle rigidity, and postural instability, has long been recognized as hallmarks of PD. However, clinical features of PD include non-motor symptoms, such as olfactory dysfunction, pain, and sensory disturbances, and gastrointestinal (GI) dysfunction. Recently, the GI tract, enteric nervous system (ENS), gut microbiota, and a cross-talk of gut-brain have become a spotlight as a potential mechanism underlying the development of PD. Thus, NGPs have been focused on a new possible approach for PD treatment.
Fig.1 The role of gut microbiota in the pathogenesis of Parkinson's disease. (Gazerani, 2019)
Human GI tract hosts a diverse population of bacterial species, collectively called human gut microbiota, where a symbiosis exists between the host and bacteria. Maintenance of a healthy microbiota is important for gut barrier integrity, immunity, function, metabolism, and the gut-brain axis. A potential role of this axis in several central nervous systems (CNS) -associated disorders have been highlighted, including in multiple sclerosis and PD. Alterations found in gut microbiota, including the number and composition of gut microbiota and microbial metabolites, have been considered as valuable signatures for early diagnosis of several neurodegenerative disorders, including PD. NGPs treatment has also been proposed as one of the diverse range of interventions targeting microbiota.
Lactobacillus reuteri can accelerate gastric emptying and improves regurgitation in infants. This might have an application for PD because delayed gastric emptying is common in patients with PD and generally reduces the absorption of PD medications including levodopa.
PD patients who are infected by Helicobacter pylori have lower absorption of L-DOPA. Eradication of Helicobacter pylori by the aid of some probiotics might then be useful in these patients. Probiotic Bifidobacterium bifidum CECT 7366 Strain affects Helicobacter pylori and could be a potential option for future research in PD.
In a germ-free mice model, the administration of Lactobacillus plantarum PS128 was used to investigate emotional behaviors in the response of gut-brain axis modulation. Results from this study presented an improvement in anxiety-like behaviors.
A randomized, double-blind, placebo-controlled clinical study has shown effects of a probiotic product in capsule format (containing Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus reuteri, and Lactobacillus fermentum) on clinical and biochemical profiles (including metabolic parameters) in PD. Administration of probiotics for 12 weeks resulted in favorable impacts on MDS-UPDRS (Movement Disorders Society-Unified Parkinson's Disease Rating Scale), high-sensitivity C-reactive protein (hs-CRP), blood glutathione (GSH), malondialdehyde (MDA), and insulin metabolism but did not affect other metabolic parameters.
Creative Biolabs has been devoted to the study of interactions between microbiota and the host immune system for years. With a number of excellent scientists specialized in NGP development, we are capable of providing high-quality services to global researchers. Our services at Creative Biolabs include but not limited to:
NGPs treatment is one of the possible methods for PD therapy. Creative Biolabs has years of industrial experience and we have accomplished lots of projects. Our scientists are confident in providing high-quality NGPs development services to meet our global customers' detailed requirements.
If you are interested in our services, please feel free to contact us.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.